For the founders of Horus Pharma, Martine and Claude Claret, growth is based on the international expansion of the group, in order to extend the influence of innovation: p>
"Expansion into international markets demonstrates our commitment to support innovation in ophthalmology through an unparalleled network of specialised partners”.
International expansion is becoming a key business objective. Though the laboratory’s international expansion began in 2010 in Western Europe, today it takes on a new dimension with the signing of distribution agreements in Eastern Europe and across the Atlantic. .
In 2013, Horus Pharma crossed the Atlantic by entering into an exclusive distribution agreement for Ilast products with Paragon Biotech Lab, based in Portland, Oregon. This first step in North America constitutes a turning point for the Horus Pharma Group, which accesses the world's largest market in the field of ophthalmology. In 2014, the Group’s network grew to the East by welcoming the Russian distributor Nova Medica.
2015 marks another key milestone for Horus Pharma with the launch of first European subsidiaries.
Convinced that innovation and the sharing of skills transcend borders, Horus Pharma is always looking for new international partners. Are you interested in collaborating? Feel free to contact us at firstname.lastname@example.org
Though our eye is on the international market, the foundations of Horus Pharma remain firmly anchored in France, where the laboratory has built a strong national network bringing together research sites, academic structures, health institutions, patient associations and manufacturing sites in subcontracting. With over 60% of its annual production units carried out in France, Horus Pharma remains true to its values and its roots, valuing the expertise and local know-how above all, to help bring them together and to offer them international exposure.